{"disease":{"id":"wet-age-related-macular-degeneration","name":"wet age related macular degeneration"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04847895","title":"Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications","phase":"","overall_status":"COMPLETED","enrollment_count":5500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06184360","title":"Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)","phase":"","overall_status":"COMPLETED","enrollment_count":2079,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03939767","title":"Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":1563,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01986907","title":"Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1049,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01914380","title":"Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":988,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04270747","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04480463","title":"A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Sam Chun Dang Pharm. Co. Ltd.","has_results":true},{"nct_id":"NCT04964089","title":"A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":557,"lead_sponsor_name":"Kodiak Sciences Inc","has_results":true},{"nct_id":"NCT05439629","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":488,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT05480293","title":"This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":446,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT07389577","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":443,"lead_sponsor_name":"Jecho Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05297292","title":"A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":433,"lead_sponsor_name":"Mabwell (Shanghai) Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05727397","title":"Efficacy and Safety of RC28-E Versus Aflibercept","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":432,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT05345236","title":"A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01972789","title":"Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":349,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04857177","title":"A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Chong Kun Dang Pharmaceutical","has_results":false},{"nct_id":"NCT06717139","title":"Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"St. Erik Eye Hospital","has_results":false},{"nct_id":"NCT07185841","title":"Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Fujian Haixi Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT07484074","title":"A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Ollin Biosciences, Inc.","has_results":false},{"nct_id":"NCT03382587","title":"Observational Study to Assess Intravitreal Aflibercept Injections Used in a \"Treat and Extend\" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients","phase":"","overall_status":"COMPLETED","enrollment_count":163,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05381948","title":"Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"EyePoint Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04685369","title":"Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers","phase":"","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Brugmann University Hospital","has_results":false},{"nct_id":"NCT03790852","title":"Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":121,"lead_sponsor_name":"Kodiak Sciences Inc","has_results":false},{"nct_id":"NCT04594681","title":"A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":116,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT04126317","title":"Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT03290794","title":"Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04468997","title":"The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":67,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT04564937","title":"The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":66,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT03423823","title":"Ziv-aflibercept Efficacy in Better Regulating AMD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Kapil Kapoor","has_results":false},{"nct_id":"NCT04832724","title":"RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07178249","title":"Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Guangzhou Jiayin Biotech Ltd","has_results":false},{"nct_id":"NCT04504123","title":"MMP-9 Inhibition for Recalcitrant Wet AMD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Iowa","has_results":false},{"nct_id":"NCT07390253","title":"Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Vienna Institute for Research in Ocular Surgery","has_results":false},{"nct_id":"NCT03312283","title":"Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05141994","title":"Clinical Study on the Efficacy and Safety of BAT5906 Injection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT06969001","title":"Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"SCAI Therapeutics","has_results":false},{"nct_id":"NCT06859515","title":"A Long-term Follow up Study of EXG102-031 in Participants With wAMD","phase":"","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Guangzhou Jiayin Biotech Ltd","has_results":false},{"nct_id":"NCT03066258","title":"Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"REGENXBIO Inc.","has_results":true},{"nct_id":"NCT02257632","title":"Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06839339","title":"Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Beijing Anlong Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04270669","title":"Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT07501052","title":"Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Sam Chun Dang Pharm. Co. Ltd.","has_results":false},{"nct_id":"NCT06704009","title":"NT-101 Topical Ophthalmic Solution in Patients With Wet AMD","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"NexThera Co., Ltd.","has_results":false},{"nct_id":"NCT03558061","title":"Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Alkahest, Inc.","has_results":true},{"nct_id":"NCT03748784","title":"ADVM-022 Intravitreal Gene Therapy for Wet AMD","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT03558074","title":"Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Alkahest, Inc.","has_results":true},{"nct_id":"NCT03585556","title":"AAVCAGsCD59 for the Treatment of Wet AMD","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04884399","title":"Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Shanghai Biomabs Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04645212","title":"Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT06707753","title":"Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Beijing Anlong Biopharmaceutical Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}